News

Public · Published

KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy

Merck said its Phase 3 KEYNOTE-C93 trial showed KEYTRUDA as a monotherapy reduced the risk of disease progression or death by 43% versus platinum doublet chemotherapy in certain patients with advanced or recurrent endometrial cancer with dMMR tumors.

Published:

Updated:

What happened

Merck said its Phase 3 KEYNOTE-C93 trial showed KEYTRUDA as a monotherapy reduced the risk of disease progression or death by 43% versus platinum doublet chemotherapy in certain patients with advanced or recurrent endometrial cancer with dMMR tumors.

Confirmed

Global impact / market context

A 43% lower risk of progression or death, supported by a statistically significant result, could strengthen KEYTRUDA's role in earlier treatment of dMMR endometrial cancer, potentially supporting Merck's oncology revenue and use of capital spending on further immunotherapy trials.

Analyst inference

The results were presented at ESMO Congress 2026 and published in The Lancet, which may raise investor attention to Merck's oncology pipeline and to competing treatments for endometrial cancer, affecting how investors position shares relative to other drugmakers.

Analyst inference

What to watch

  1. Merck plans to present the late-breaking KEYNOTE-C93 results at the ESMO Congress 2026 Presidential Symposium and has simultaneously published them in The Lancet. Confirmed
  2. Watch whether Merck submits these dMMR endometrial cancer results to regulators to seek approval for KEYTRUDA as a monotherapy in this setting, which means broader commercial use. Proposed
  3. Track whether longer follow-up confirms the 38.2-month median progression-free survival for KEYTRUDA versus 8.4 months for chemotherapy, since durable benefit could influence prescribing and revenue. Analyst inference

Evidence

  • Original source link unavailable